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Chorioamnionitis is a major cause of preterm birth and brain injury. Bacterial invasion
of the chorion and amnion, and/or the placenta, can lead to a fetal inflammatory
response, which in turn has significant adverse consequences for the developing fetal
brain. Accordingly, there is a strong causal link between chorioamnionitis, preterm brain
injury and the pathogenesis of severe postnatal neurological deficits and cerebral palsy.
Currently there are no treatments to protect or repair against brain injury in preterm infants
born after pregnancy compromised by intrauterine infection. This review describes the
injurious cascade of events in the preterm brain in response to a severe fetal inflammatory
event. We will highlight specific periods of increased vulnerability, and the potential effects
of therapeutic intervention with cell-based therapies. Many clinical trials are underway to
investigate the efficacy of stem cells to treat patients with cerebral palsy. Stem cells,
obtained from umbilical cord tissue and cord blood, normally discarded after birth, are
emerging as a safe and potentially effective therapy. It is not yet known, however, which
stem cell type(s) are themost efficacious for administration to preterm infants to treat brain
injury-mediated inflammation. Individual stem cell populations found in cord blood and
tissue, such as mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs),
have a number of potential benefits that may specifically target preterm inflammatory-
induced brain injury. MSCs have strong immunomodulatory potential, protecting against
global and local neuroinflammatory cascades triggered during infection to the fetus. EPCs
have angiogenic and vascular reparative qualities that make them ideal for neurovascular
repair. A combined therapy using both MSCs and EPCs to target inflammation and
promote angiogenesis for re-establishment of vital vessel networks is a treatment
concept that warrants further investigation.
Keywords: preterm, brain, inflammation, chorioamnionitis, stem cells, endothelial progenitor cells, mesenchymal
stem cells, cerebral palsy
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INTRODUCTION
Nearly 10% of all births are preterm, <37 weeks completed
gestation (Beck et al., 2010). The survival of very preterm infants
(28–32 weeks gestation) and extremely preterm infants (<28
weeks gestation) has improved over the past several decades
(Miyazaki et al., 2007; Tita and Andrews, 2010), however
prematurity still accounts for up to 70% of perinatal deaths
and, in survivors, adverse neurodevelopmental outcomes, and
cerebral palsy (CP; Singh et al., 2011). After birth there are no
clinical treatments to protect or repair the brain of preterm
infants. Moreover, whilst survival rates for very/extremely
preterm infants have improved, a recent review revealed that
the rate of CP in this population remains static (Oskoui et al.,
2013). It is known that 40–70% of cases of preterm birth
are complicated by inflammation affecting the placenta and its
membranes, termed chorioamnionitis (Tita and Andrews, 2010).
Chorioamnionitis and preterm birth are strongly linked, with
rates of chorioamnionitis inversely correlated to fetal gestational
age and preterm birth (Galinsky et al., 2013). Chorioamnionitis
is implicated in 66% of preterm births at 24 weeks or earlier,
with this figure decreasing to 16% by 34 weeks gestation
(Lahra and Jeffery, 2004). Independently, both preterm birth
and chorioamnionitis contribute to brain injury in infants born
preterm and the development of subsequent neurological deficits.
However, when these occur simultaneously, the degree of brain
injury is more severe.
Acute inflammation of the feto-placental environment,
broadly describing chorioamnionitis, is a principal contributor
to premature rupture of membranes (PROM) and spontaneous
preterm birth (Romero and Mazor, 1988; Tita and Andrews,
2010). PROM does not have to be present for a diagnosis of
chorioamnionitis—more than one third of patients that deliver
preterm will have intact placental membranes—yet 13% of these
patients will later be diagnosed as having chorioamnionitis
(Goncalves et al., 2002). Nevertheless, PROM is the most easily
identifiable factor for indicating chorioamnionitis, which may
be accompanied by vaginal bacterial abnormalities, meconium
stained amniotic fluid, prolonged labor and altered placental
histopathology (Tita and Andrews, 2010).
Chorioamnionitis causes fetal inflammation and injury to
the immature brain, increasing the likelihood of intraventricular
hemorrhage (IVH) and diffuse white matter injury (Wu and
Colford, 2000). In addition to the fetal inflammatory response,
hypoxia also contributes to perinatal brain injury associated with
chorioamnionitis and preterm birth (Khwaja and Volpe, 2008).
Abbreviations: CP, Cerebral palsy; PROM, premature rupture of membranes;
IVH, intraventricular hemorrhage; BBB, blood-brain barrier; FIRS, fetal
inflammatory response syndrome; IL, interleukin; PVL, periventricular
leukomalacia; GMH, germinal matrix hemorrhage; LPS, lipopolysaccharide; TLR,
toll-like receptor; ROS, reactive oxygen species; HIF-1α, hypoxia-inducible factor
1α; OPCs, oligodendrocyte progenitor cells; PRR, pattern recognition receptor;
HIE, hypoxic-ischemic encephalopathy; ODD, oxygen-dependant domains; UCB,
umbilical cord blood; EPCs, endothelial progenitor cells; MSCs, mesenchymal
stem cells; MHC, major histocompatibility complex; HE, hepatocyte growth
factor; BDNF, brain derived neurotrophic factor; VEGF, vascular endothelial
growth factor; GDNF, glial-derived neurotrophic factor; PGE2, prostaglandin;
SDF-1, stromal cell-derived factor; IGF-1, insulin-like growth factor; CXCR-4,
C-X-C chemokine receptor-4.
Both fetal inflammation and hypoxia mediate neuropathology,
acting to induce breakdown of the blood brain barrier (BBB),
neuroinflammation, and oligodendrocyte cell damage (Malaeb
and Dammann, 2009). With no specific treatments available to
protect the brain injury caused by infection, most cases involving
ruptured membranes require the infant to be delivered early
to reduce the risk of further compromise. However, by the
time of delivery, the infant has been exposed to inflammatory
mediators that pose significant risks to the developing brain. The
current standard of care following diagnosis of chorioamnionitis
during pregnancy is focused on timely delivery of the infant.
Accordingly, fetuses that have been exposed to chorioamnionitis
are often further compromised by preterm birth (Guzick and
Winn, 1985), and the subsequent risks for the immature brain.
In particular, chorioamnionitis and preterm birth both have
profound adverse effects on the developing white matter of
the brain, which is the key etiology in the pathogenesis of CP
(Kaukola et al., 2006).
CHORIOAMNIONITIS
Chorioamnionitis is characterized as intra-amniotic infection
where bacterial invasion results in acute inflammation of
the placenta and/or fetal membranes (Tita and Andrews,
2010). The bacterial species Mycoplasma is the most common
bacterial form present in cases of chorioamnionitis, however
multiple microorganisms may be involved (Romero and Mazor,
1988; Czikk et al., 2011). These include Streptococcus hominis,
Fusobacterium, Gardnerella vaginalis, and Escherichia coli. Up to
25% of all preterm births <37 weeks gestation are complicated
by chorioamnionitis (Goncalves et al., 2002). In some cases,
chorioamnionitis is diagnosed before labor through maternal
symptoms (referred to as clinical chorioamnionitis), and may
be confirmed after delivery by histologic analysis of the
placenta. Most cases are termed subclinical chorioamnionitis,
with no obvious symptoms during pregnancy, but placental
histopathology after preterm birth revealing significant levels of
activated neutrophils and macrophages, indicative of infection
(Miyazaki et al., 2007; Gisslen et al., 2016).
Neonates who are born with clinical chorioamnionitis
may show symptoms of infection, including increased heart
rate, decreased blood pressure and impaired cardiac output
(Yanowitz et al., 2002). However, subclinical and undiagnosed
infection is also implicated in serious adverse perinatal outcomes
(Gibbs, 2001). One population-based study involving >250,000
Australian births found an overall incidence of subclinical
histologic chorioamnionitis of 22.6%, however less than half of
these cases showed a fetal inflammatory response as evidenced
by the presence of infection in the umbilical cord and/or chorion
(Gordon et al., 2011). The presence of a fetal inflammatory
response was strongly associated with spontaneous preterm
labor, but chorioamnionitis in the absence of a fetal inflammatory
response was correlated to unexplained fetal death (Gordon
et al., 2011). These data demonstrate that chorioamnionitis
is a significant contributor to stillbirth and adverse neonatal
outcomes, often mediated by fetal inflammatory response
syndrome.
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Fetal Inflammatory Response Syndrome
(FIRS)
FIRS describes inflammation of multiple fetal organs in utero as
a result of systemic immune activation, and is associated with
increased preterm perinatal morbidity and mortality (Romero
and Mazor, 1988; Bashiri et al., 2006). FIRS is defined by elevated
interleukin-6 (IL-6) fetal plasma concentration in the presence of
chorioamnionitis, PROM or preterm delivery (Madsen-Bouterse
et al., 2010). The adverse consequences of fetal exposure to
inflammation can be significant for the developing brain. There
is a strong association between elevated cord blood IL-6 and the
risk of CP for the preterm neonate (Yoon et al., 1995).
FIRS is present in the majority of fetuses exposed to
chorioamnionitis (Gomez et al., 1997) principally because the
fetus is in contact with an infectious amniotic fluid and
membrane environment. Pro-inflammatory cytokines, such as
IL-6, may also be present in the uteroplacental circulation (Yoon
et al., 2000; Andrews et al., 2006). Where chorioamnionitis is
present, the fetal lungs, skin, and gut have been shown to initiate
a local inflammatory response, which in turn can evolve into
a systemic response and FIRS (Kallapur et al., 2014). In some
cases, however, FIRS may also be stimulated by blood-borne
maternal or placental microorganisms (Tita and Andrews, 2010).
Whatever the primary source, FIRS, and in particular elevated
fetal circulating IL-6 concentration, is closely associated with
preterm birth and adverse neonatal outcomes (Hofer et al.,
2013). Specifically, high levels of fetal IL-6 are linked to fetal
cardiovascular dysfunctions, and lung and brain pathologies
(Galinsky et al., 2013).
Brain Injury
Chorioamnionitis and FIRS are highly associated with neonatal
brain injury and the subsequent diagnosis of CP (Shatrov et al.,
2010; Kuypers et al., 2012). This is the result of many contributing
factors and downstream inflammatory cascades that occur
followingmicrobial invasion of the feto-placental unit (Figure 1).
Although primarily harmful, inflammatory cascades also involve
the recruitment of immune cells and release of growth factors
to areas of damage that stimulate endogenous brain repair
and regeneration (Dammann and O’Shea, 2008). However,
when brain inflammation becomes prolonged or severe, it
can exacerbate damage through further influx of cytokines,
chemokines, and other inflammatory mediators released from
glial cells (Stoll et al., 2003).
Increased circulating pro-inflammatory cytokines, including
IL-6, cross the BBB, increase BBB leakiness, and induce a
neuroinflammatory response through the activation of microglia
and astrocytes (McAdams and Juul, 2012; Schmidt et al.,
2016). Pro-inflammatory cytokines that access the fetal brain
then act upon vulnerable cell populations, disrupting normal
maturation, and development of the white matter in particular
(Dammann and Leviton, 1997). Accordingly, the most common
neuropathology that occurs in human infants who were
exposed to chorioamnionitis is white matter injury, diagnosed
by cranial ultrasound, and MRI (Gaudet et al., 2009). The
most severe white matter brain injury is generally observed
FIGURE 1 | Contributing factors of brain injury to the fetus following
chorioamnionitis. Bacterial entry during fetal development can occur by
many different routes including the placental circulation and through placental
membranes (indicated by the red dots). The invasion of microorganisms
results in inflammation of the feto-placental unit and the development of fetal
inflammatory response syndrome (FIRS). Within the fetus, this can cause
hypoxia, blood vessel damage, and blood brain barrier (BBB) compromise.
These common responses lead to long-term alterations in white matter
development within the fetal brain.
in infants born between 24 and 32 weeks gestation (Volpe,
2009b). Either cystic or diffuse white matter injury bordering
the ventricles of the brain, so called periventricular white
matter lesions, or periventricular leukomalacia (PVL), is the
most common form of brain injury detectable on MRI in
patients born preterm and in those with CP (Volpe, 2001;
Mann and Horber, 2007). Up to 90% of preterm babies who
develop CP will have diffuse or cystic periventricular white
matter injury (Krägeloh-Mann and Horber, 2007). It is well-
described that this selective vulnerability of the developing white
matter of the brain to an inflammatory stimulus is due to
cell loss and/or interference with oligodendrocyte maturation
(Back et al., 2007). The function of mature oligodendrocytes is
to myelinate the developing axons, but impaired myelination
is the key pathological feature of PVL. Mature, myelinating
oligodendrocytes are present within the periventricular white
matter region of the human brain from about 32 weeks gestation
but, prior to this, pre-oligodendrocytes predominate (Back et al.,
2001). Acute vulnerability of pre-oligodendrocytes is attributed
to the predominance of these cells within the white matter
(∼90% of total oligodendrocytes) between 23 and 32 weeks
gestation, with very few mature myelinating oligodendrocytes.
If pre-oligodendrocyte development is disrupted, the normal
maturation toward the myelinating cells is inhibited. In turn,
hypomyelination and disorganization of the white matter is
highly correlated with cognitive and functional impairments in
children with CP (Hoon et al., 2009).
In addition to PVL, hemorrhage (germinal matrix or
intraventricular hemorrhage, GMH/IVH) is a critical contributor
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to poor neurodevelopmental outcome in preterm infants
who were exposed to chorioamnionitis in utero. Within
the preterm brain, the blood vessels have a relatively low
density compared to the term brain, and are easily damaged
by inflammatory stimuli which then increases the risk of
bleeding and injury to surrounding white matter (Brew
et al., 2014). The etiology of hemorrhage within the white
matter of preterm infants is multifactorial, but is principally
contributed by low vascular density, immaturity of cerebral
vessels (with ongoing angiogenesis and vasculogenesis), together
with blunted vasoreactivity (Brew et al., 2014). Pathological
stimuli, including acute periods of hypoxia-ischemia, and influx
of pro-inflammatory cytokines, contributes to brain bleeds with
the immature white matter because of the inability of immature
vessels to adequately adapt to changing perfusion pressure (Børch
et al., 2010). Consequently, brain bleeds occur in up to 50%
of infants born preterm at a very low birth weight and can
contribute to PVL, with the white matter adjacent to the lateral
ventricles becoming coagulated and necrotic (Volpe, 2009a). In
contrast, in the very preterm period, the gray matter including
cortical regions is highly vascularized and able to withstand
injury or mild periods of hypoxia or inflammation (Brew et al.,
2014).
Preterm birth and chorioamnionitis is characterized by
periods of brain hypoxia, either from inflammation of the
placenta disrupting blood flow to the fetus or as a result
of inflammation (Baburamani et al., 2012; Stanek, 2013). In
response to hypoxia, brain vasculogenesis is upregulated in an
attempt to increase brain perfusion, such that capillary networks
must sprout and develop to support oxygen and nutrient
requirements of the brain (Baburamani et al., 2012). However,
these new vessels tend to be more fragile and susceptible to
pericytes detachment and cytokine damage. Periods of hypoxia
and fluctuations in cerebral oxygenation are exacerbated after
birth in preterm infants who require mechanical or assisted
ventilation (Barton et al., 2014). This can cause brain damage
through oxidative stress and inflammation (Polglase et al., 2012).
Therefore, in preterm infants with the additional complication
of chorioamnionitis, hypoxia as well as cerebral inflammation
causes more severe brain injury (AdamsWaldorf and McAdams,
2013).
EXPERIMENTAL ANIMAL MODELS TO
EXAMINE CHORIOAMNIONITIS
Animal models of chorioamnionitis and fetal inflammation
greatly assist the examination of mechanisms underlying
neuroinflammation and the progression toward perinatal brain
injury. Animal models are critical in assessing the therapeutic
potential of various treatments, and lipopolysaccharide (LPS)
is one of the most common experimental compounds used
to mimic infection. LPS is a component of gram-negative
bacterial wall and acts via toll-like receptors (TLRs, specifically
TLR 4) to illicit a strong inflammatory response (Briscoe
et al., 2006). Experimentally, sterile LPS can be administered
during pregnancy into the amniotic cavity or directly to the
fetus, to induce a fetal inflammatory response that mimics
the inflammatory milieu and white matter brain injury that
is observed in human chorioamnionitis (Grigsby et al., 2003;
Duncan et al., 2006).
Animal models used to induce chorioamnionitis and a fetal
inflammatory response have identified three critical mechanistic
components that mediate the progression of perinatal brain
injury; breakdown of the BBB, neuroinflammation, and hypoxia,
which together contribute to neuropathology (Duncan, 2002;
Back and Rivkees, 2004; Schmidt et al., 2016).
Breakdown of the Blood Brain Barrier
(BBB)
The BBB provides the structural interface between circulating
blood and cerebral tissue/cerebral extracellular fluid via a cellular
barrier composed of endothelial cells (Ballabh et al., 2004).
The BBB is a selective barrier, predominantly regulated by
gap junctions between endothelial cells, externally lined by
perivascular pericytes, and astrocytes, which together form the
neurovascular unit (Weiss et al., 2009). In its role of physical
separation of the circulatory components from cells within
the brain, the BBB maintains brain homeostasis by preventing
peripheral toxins and cells from entering the brain, removing
waste products from the brain and regulating fluid and metabolic
balance (Abbott et al., 2006). Under pathological conditions the
BBB may become compromised, and this is shown to be the case
in response to a severe fetal inflammatory insult (Ballabh et al.,
2004).
Deterioration of the BBB occurs when the tight junctions
between endothelial cells are compromised, particularly when
membrane proteins are damaged (Nitta et al., 2003; Weiss
et al., 2009). BBB compromise can be caused by innate immune
activation and by the release of free radicals, prostaglandins,
interleukins, glutamate, histamine, and many other substrates
(Abbott et al., 2006). Whilst it is not really understood how, or
if, endotoxins such as LPS infiltrate the brain, they may elicit
damage through direct binding of TLRs on microglia within the
brain or via cerebral endothelial cells of the BBB.
Neuroinflammation
As the brain matures, it is able to counter invading pathogens
through innate immunity involving the pattern recognition
receptors (PRRs), TLRs (Chen and Nuñez, 2010). However,
when activation of these receptors is sustained, BBB permeability
is enhanced, and peripheral immune cells gain access to the
developing brain (Hagberg et al., 2015). Ongoing TLR activation
on immune cells is associated with increased immune cell
infiltrates, microglial activation and cytokine release (Cai et al.,
2000). It is suggested that, in particular, TLR3 protein expression
in the brain is upregulated in cases of white matter injury
and invading pathogens in the preterm brain (Vontell et al.,
2013). TLR3 is implicated in normal neural cell differentiation
and proliferation. When injury to the premature brain occurs,
redistribution of TLR3 on microglia over neurons can result
in morphological changes in the white matter through the
inhibition of axonal growth (Cameron et al., 2007). This is
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hypothesized to be one of the main reasons that the brain has
such limited regenerative capacity following injury.
Microglia are the resident immune cells in the brain
that rapidly respond to inflammation or changes in the
brain microenvironment (Kreutzberg, 1996). When the BBB
becomes compromised, invading blood compounds may activate
microglia rapidly; potentially within 60 s (Davalos et al.,
2005). Aggregates of activated microglia are indicative of
neuroinflammation and ongoing tissue injury through cytokine
release (Verney et al., 2012; Adams Waldorf and McAdams,
2013). Microglial activation and cytokine release is also
brain region specific; in fetal preterm sheep, LPS injected
intra-amniotically increases IL-1β in the fetal brain cortex,
hippocampus and cerebellar regions within 2 days (Strackx
et al., 2015). After 7 days, microglial and astrocyte proliferation
in damaged regions was evident with apoptosis and reduced
myelination occurring in the subcortical white matter and
hippocampus.
The key cytokine IL-6, as well IL-1α, IL-1β, and IL-18 are
released from activated immune cells such as microglia, mast
cells, and neutrophils, which in turn stimulate the release of
reactive oxygen species (ROS), TNF, and excitatory amino acid
agonists including glutamate, that act together to initiate neural
cell apoptosis (Bona et al., 1999; Hagberg et al., 2015). These
substances can have direct effects on vulnerable oligodendrocyte
progenitor cells (OPCs). Three changes occur to OPCs that
directly affect white matter development in the premature brain
following inflammation: depletion of actively proliferating OPCs,
maturational arrest of OPCs, and death of OPCs (Billiards et al.,
2008; Volpe et al., 2011). Pro-inflammatory cytokine release and
binding of IL1-β and TNF-α to their respective receptors TNF-R1
and IL-1R1 situated on oligodendrocytes is a principal cause of
damage to these cells (Deng et al., 2014). It is known that periods
of hypoxia lead to upregulation of TNF-R1 and IL-1 R1 in the
brain. Neighbouring reactive astrocytes release IL1-β and TNF-
α, with signaling through their receptors causing downstream
activation of apoptotic pathways and proliferative inhibition of
oligodendrocytes (Deng et al., 2014).
Hypoxia
Animal models of perinatal compromise have elucidated
that a fetal inflammatory response directly causes brain
hypoxia-ischemia, and also results in an oxygen-independent
inflammatory hypoxia, driven via activation of the hypoxia-
inducible factor 1α (HIF-1α) pathway (Huang et al., 1998;
Duncan, 2002; Peebles et al., 2003). Independently, each of these
may contribute to the progression of white matter injury. TLR
and NF-κB on placental tissues are activated and cytokine release
is upregulated within the placenta and membranes (Briscoe
et al., 2006). Pro-inflammatory cytokines cause physical and
functional changes in placental tissues, with arteries and veins
in the umbilical cord and placenta becoming inflamed (Tita and
Andrews, 2010). Inflammation of the cord and the placenta can
restrict blood flow and affect placental function. This can lead
to acute or prolonged periods of hypoxia-ischemia during fetal
gestation.
Within the brain, oxygen-independent hypoxia can occur as
a consequence of neuroinflammation due to pro-inflammatory
cytokines, ROS, and excitotoxic substances that stimulate
anaerobic metabolism. At least in part, this is attributable
to the release of nitric oxide from astrocytes following
neuroinflammation, causing mitochondrial failure (Ferriero
et al., 1996). Hypoxia also inhibits the degradation of HIF-
1α (Huang et al., 1998) which may have duel effects to
promote repair but also to induce injury (Shi, 2009). For
example, HIF-1α regulates genes that mediate cell proliferation
and angiogenesis; each of these processes are essential to
tissue repair following insult, but aberrant cell proliferation
is associated with maturational arrest of oligodendrocytes,
and immature angiogenic blood vessels are associated with
hemorrhage (Segovia et al., 2008; Brew et al., 2014). Hypoxia is
also associated with calcium influx after inflammation-induced
glutamate release from immune cells, causing excitotoxicity
and resulting in Bax (pro-apoptotic protein) translocation
to the mitochondria on OPCs and release of cytochrome-c.
These observations indicate that hypoxia has the ability to
impair the development of OPCs via activation of cell death
through enzymes caspase-9 and caspase-3 (Simonishvili et al.,
2013).
It is difficult to tease apart the individual contribution to
brain injury that breakdown of the BBB, neuroinflammation,
and hypoxia each make. Nonetheless, novel discoveries in large
animal models using LPS to stimulate a fetal inflammatory
response have revealed that inflammation and hypoxia can
independently result in significant white matter injury (Duncan,
2002; Duncan et al., 2006). However, it is most likely that, in
preterm infants exposed to chorioamnionitis, both inflammation
and hypoxia contribute to the pathogenesis of white matter
injury.
There are no approved therapies that can be offered to infants
born preterm following exposure to chorioamnionitis, despite
our knowledge that these infants are at the greatest risk for brain
injury.
STEM CELL THERAPIES
Stem cells have emerged as a promising potential neuroprotective
and neuroreparative treatment. Stem cells have the potential for
self-renewal as well as the ability to differentiate into mature cell
lineages (Bruder et al., 1997; Shen et al., 2004): a feature which
allows stem cells to be beneficial for repair, remodeling or new
tissue growth after tissue and cell damage. Stem cells also function
indirectly to modify endogenous cell responses and can secrete
growth factors and cytokines that mediate tissue repair (Baraniak
and McDevitt, 2010). Umbilical cord blood (UCB) stem cells,
in particular, have a number of benefits that support their
therapeutic use for infants after birth who are deemed at high
risk for brain injury following antenatal or birth complications.
Clinical use of UCB has been well-described since the first UCB
cell transplantation in 1988 (M-Reboredo et al., 2000). UCB is a
commonly used therapy in a range of hematological conditions
like blood cancers as well as graft-vs. host disease. The use of
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UCB and placental stem cells avoids issues that surround the
use of bone marrow derived, and other forms of stem cells that
necessitate invasive collection, as the umbilical cord and placenta
are normally discarded at birth. Additionally, due to the primitive
nature of these cells and a lack of immune recognition surface
antigens present on most adult cells, the risk of graft vs. host
disease is reduced (Gluckman et al., 1997). Therefore, the risks
associated with other more mature types of tissue transplant are
minimized.
UCB Clinical Trials for CP
Clinical trials have demonstrated the safety of UCB
administration to children with established CP (Lee et al.,
2012; Feng et al., 2015; Novak et al., 2016). Currently, however,
it remains unclear how effective UCB could be in the setting
of chorioamnionitis and preterm birth. No trials have been
established to assess the efficacy of UCB or stem cell therapies for
white matter injuries in preterm newborns. There are however,
a number of trials in children and adults that suggest these cells
may be an effective therapy.
Novak and colleagues recently reviewed the evidence for
the use of stem cells in improving gross motor function in
children with CP (Novak et al., 2016); four randomized clinical
trials and one non-randomized clinical trial were included for
analysis. Two of these trials involved the use of allogeneic UCB
transplantation (Min et al., 2013; Kang et al., 2015). All trials
reported improvements in motor function following stem cell
therapy. However, the two trials using UCB found that treatment,
either administered alone or with rehabilitation, resulted in
greater motor function improvements than rehabilitation alone.
Combining the two studies allowed for the calculation of an odds
ratio of 2.62 in favor of UCB therapy for CP. All stem cell trials
reported low adverse events (<3%); these included vomiting,
breathing difficulties, skin, or eye reactions, with no reported
differences in serious adverse events such as hospitalization and
seizures. This meta-analysis concluded that stem cell treatment
in patients with established CP made a significant short-term
improvement in gross motor function after 6 months. We await
the results from longer follow-up (>2 years) to ascertain the
long-term benefit of stem cell treatment.
Information regarding benefits or risks associated with
allogeneic UCB transplantation are pivotal to understanding
the types of cell therapy that may be suitable for preterm
newborns. In the case of treating those vulnerable to preterm
brain injury following chorioamnionitis, allogeneic cell treatment
may be the most appropriate. Preterm babies are not the best
candidates for autologous UCB transplants for a number of
reasons; (i) collection volumes of UCB are proportional to
gestational age and preterm birth is therefore implicated in
low collection volumes (Wen et al., 2012; Mazzoccoli et al.,
2016), (ii) it is unknown how maternal and fetal complications,
including gestational diabetes, intrauterine growth restriction,
preeclampsia, and chorioamnionitis, predominant in preterm
births, alter the relative proportion of stem and immune cells
(Wen et al., 2012; Li et al., 2014) and (iii) it has been suggested
that, in large clinical trials, such as the Duke University UCB trial
(clinicaltrails.gov), recruitment of participants was significantly
lower than anticipated (63 recruited vs. a planned recruitment of
120) due to the lack of autologous cord blood storage in children
that go on to be diagnosed with CP (Duke TranslationalMedicine
Institute Website, 2012).
DESIGNING TARGETED STEM CELL
THERAPIES: MSCS AND EPCS
As described above, a main injurious cascade associated with
chorioamnionitis and fetal brain injury is inflammation. The
major mechanism of action of UCB cells is its anti-inflammatory
capacity. This is attributable to the many immunomodulatory
cells present in UCB, including mesenchymal stem cells (MSCs;
Liao et al., 2013; Zhao et al., 2016). A further injurious
cascade related to chorioamnionitis is hypoxia and blood vessel
damage. A potent and well-described population of cells in UCB,
namely endothelial progenitor cells (EPCs), function to promote
neovascularization and vessel repair (Kalka et al., 2000;Murohara
et al., 2000). Therefore, a targeted cell therapy, using the cell
properties of EPCs and MSCs may be favorable for preterm
infants exposed to chorioamnionitis in utero (Broxmeyer, 2005;
Mei et al., 2010).
MSCs
MSCs are readily sourced from placental tissues, including the
umbilical cord, as well as adult bone marrow and adipose tissue
(Hass et al., 2011). The neuroprotective and reparative capacity
of MSCs is primarily facilitated by their anti-inflammatory
properties and their capacity to secrete neurotrophic and anti-
apoptotic factors (Mahmood et al., 2004; van Velthoven et al.,
2010). MSCs are well-tolerated due to their low expression of
cell surface molecules responsible for the initiation of immune
responses, such as low expression of human MHC class 1 and
their lack of MHC class 2 molecules (Jacobs et al., 2013).
MSCs prevent inflammatory and apoptotic processes involved
in brain injury by actively down-regulating pro-inflammatory
cytokines (Ahn et al., 2013; MacFarlane et al., 2013). This was
shown in a rodent study where intraventricular hemorrhage was
induced immediately following birth and UCB-derived MSCs
were transplanted into the brain ventricle (Ahn et al., 2013).
Treatment with MSCs suppressed the upregulation of cytokines
IL-1α, IL-1β, IL-6, and TNF-αwithin the CSF and periventricular
brain region. This resulted in an attenuation of swelling and fluid
formation around the brain and improved behavioral outcomes.
The role of MSCs in altering a systemic immune response has
been directly demonstrated in an experiment on mice with sepsis
(Mei et al., 2010). Six hours after induced sepsis, mice were
treated withMSCs derived from bonemarrow or saline (control).
Results showed that mice treated with MSCs had reduced overall
levels of circulating cytokines, down-regulation of inflammatory
mediators like IL-6, IL-1β and an up-regulation of pathways
responsible for bacterial elimination like C-C chemokine ligand 5
and Fc receptor-mediated immune-cell homing and phagocytosis
in macrophages and monocytes. This study supports the use of
MSCs for a targeted therapy against infection and inflammation.
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MSCs immunomodulatory function is multifaceted,
demonstrating not only direct secretion of anti-inflammatory
cytokines but also altering immune cell programming and
proliferation. MSCs have been shown to modify immune
function directly by impairing the differentiation of dendritic
cells, the main antigen-presenting cell in human immunity, from
monocytes (Ramasamy et al., 2007). MSCs also alter dendritic
cell release of pro-inflammatory cytokine TNF-α (Aggarwal and
Pittenger, 2005). This can exert long term immune inhibition
peripherally, which could be protective in the setting of preterm
brain inflammation. T-helper cell production of IFN-γ in
the presence of MSCs is also decreased by 50% and IL-4
production increased by over 500% (Aggarwal and Pittenger,
2005). IL-4 release promotes STAT6 pathway activation in MSCs
that leads to an increase in TGF-β production (Kyurkchiev
et al., 2014). In turn, TGF-β release from MSCs mediates
inhibition of inflammatory T-helper cell cytokines, inhibits T-cell
proliferation and increases recruitment of T-regulatory cells
which help maintain immune tolerance (Zheng et al., 2015). The
stimulation of natural killer cells in the presence of MSCs showed
a reduced level of IFN-γ secretion by more than 80%. This is
important because reducing IFN-γ release from T and natural
killer cells inhibits the direct activation of macrophages and
stops the activation of pro-inflammatory transcription factors
like NF-κβ (Mühl and Pfeilschifter, 2003). These results indicate
that MSCs have the capacity to alter macrophage function in
the setting of inflammation and brain injury, likely acting via a
reduction in immune response.
MSCs also secrete and recruit anti-inflammatory cytokines,
growth factors and neurotrophic factors, including hepatocyte
growth factor (HGF), brain derived neurotrophic factor (BDNF),
vascular endothelial growth factor (VEGF), glial derived
neurotrophic factor (GDNF), and IL-10 (Salgado et al., 2015).
This is important as exogenous MSCs can promote a more
anti-inflammatory environment within the brain, favoring
reparative mechanisms. It has been postulated that a key
immunomodulatory factor released by MSCs is prostaglandin
(PGE2), with one study showing that when PGE2 was inhibited,
the immunomodulatory effects ofMSCs was abolished (Aggarwal
and Pittenger, 2005).
If MSCs are to be used in neonates, expansion of cell
populations may be necessary to provide a therapeutic dose.
MSC colonies are only found in ∼20–30% of all UCB samples
collected from term births (Fan et al., 2009), but umbilical
cord tissue is a more readily available source of MSCs (Schugar
et al., 2009). One gram of umbilical cord tissue can yield up
to 11 million cells, of which up to 50% are characterized as
mesenchymal progenitors (Schugar et al., 2009). These cells
maintain their stem-like phenotype over multiple passages and
show high proliferative capability. It has been shown that
MSCs passaged up to six times still maintained their stem
cell-like phenotype with tri-lineage differentiation potential,
maintained expression of typical MSC surface antigens and lack
of myeloid or endothelial surface antigens (Ruan et al., 2014).
Therefore, a promising source of MSCs for expansion and use
therapeutically for preterm brain inflammation is umbilical cord
tissue.
If MSCs can be administered at a relevant time point
during peak inflammation, they may be able to reduce the
pro-inflammatory environment and protect the brain following
chorioamnionitis. A mouse model of chorioamnionitis induced
via fetal LPS exposure showed that maternal administration
of MSCs resulted in reduced IL-6 concentration in the fetal
brain (Lei et al., 2015). This was also accompanied by a
reduction in activated microglia and improved neurobehavioral
outcomes in mice. By suppressing pro-inflammatory mediators
and enhancing anti-inflammatory factors, MSCs also create a
more supportive environment for repair following brain injury.
Whilst MSCs can be administered following chorioamnionitis
to protect against inflammation-induced brain injury,
MSCs could potentially be combined with EPCs to support
other neuroreparative processes, including vascular repair.
Interestingly, MSCs and MSC-like spindle shaped cells have also
been shown to support angiogenesis in multiple studies in-vitro
when co-cultured with EPCs and also in vivo in the treatment of
experimental hindlimb ischemia (Bhang et al., 2012; Peters et al.,
2015).
EPCs
EPCs can be readily obtained from adult peripheral blood and
UCB. EPCs alone may be a promising source for the treatment
of inflammation-induced brain injury, with a number of studies
reporting that under ischemic conditions, EPCs are able to
migrate to regions of tissue damage and/or hypoxia and assist
in the neovascularization process (Kalka et al., 2000; Fan et al.,
2010).
Endogenous EPCs are well-recognized for their role in
vasculogenesis. Vascular remodeling involves the recruitment of
stem cells for the formation of new blood vessel and capillary
networks, and begins with EPCs becoming mobilized from their
primary source, bone marrow (Liu et al., 2007). Mobilization is
supported primarily by VEGF, matrix metalloproteinase-9 and
erythropoietin (Asahara et al., 1999; Dimmeler, 2010). After this
initial phase, endogenous EPCs migrate toward vessel damage by
“adhesion rolling” in which the cells attach to surface molecules
found on the blood vessel walls (Liu and Velazquez, 2008).
VEGF and multiple adhesion molecules including β2 integrins,
E-selectin, and P-selectin, assist in this process (Chavakis et al.,
2005). EPCs are then able to integrate into the injured endothelial
monolayer to support neovascularization and further release of
vascular growth factors.
In vivo animal experiments support that therapeutically
administered EPCs home to regions of tissue damage and
participate in vascularization (Kalka et al., 2000; Werner et al.,
2003). Neovascularization at sites of damaged brain tissue is vital
for cell repair, especially following inflammation and hypoxia. In
response to hypoxic injury, blood vessels proliferate and form
new networks (Baburamani et al., 2012). This is functionally
important for the rapid restoration of oxygen to the brain.
However, these newly formed capillaries are unstable and are
likely to be dangerous for brain function in the long term,
increasing the risk of intracranial hemorrhage (Ballabh, 2010).
This abnormal blood vessel development is attributed to the
decreased availability of VEGF and reduced EPC mobilization
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immediately following an insult, and is a phenomenon noted
in chorioamnionitis (Kramer et al., 2005; Mooney et al., 2014).
Thus, exogenous administration of EPCs in the preterm infant
may aid in the establishment of strengthened blood vessel
formation that creates more viable and long-lasting vascular
networks.
In addition to mediating blood vessel repair, EPCs may
have therapeutic benefits through their paracrine activity. EPCs
release multiple growth factors and cytokines that contribute
to the inhibition of cell death, increased cell proliferation, and
recruitment of local stem cells to the site of injury (Tongers et al.,
2010). Following an inflammatory or ischemic insult, in which
blood flow is impaired, endogenous endothelial cells become
activated and initially release nitric oxide, allowing for the
expansion of arterioles to compensate for vessel damage. When
this expansion is prolonged, blood vessels shunt blood around
damaged tissue where vessels have become non-functional and
collateral vasculature is formed (Schaper and Scholz, 2003).
EPCs themselves are highly receptive to the collateral response
whereby they sense stress and endothelial activation, upregulate
VEGF receptors and activate Akt signaling which promotes EPC
differentiation at sites of damage (Mogi et al., 2008; Tongers et al.,
2010). EPCs also release VEGF, stromal cell derived factor (SDF-
1), and insulin-like growth factor (IGF-1), which are reparatory
soluble factors stimulated following ischemic conditions (Urbich
and Dimmeler, 2004; Urbich et al., 2005), with each playing
a complimentary role in blood vessel repair. VEGF release is
important following brain injury, not only in the formation and
repair of blood vessels, but for stimulating axonal outgrowth
and the inhibition of hypoxic death of neurons (Sun et al.,
2003). VEGF release by EPCs also promotes neurogenesis by
direct differentiation and growth of neural precursors. SDF-1 is
necessary under inflammatory or ischemic conditions to recruit
endothelial progenitors to sites of injury via C-X-C chemokine
receptor-4 (CXCR-4; Peplow, 2014). For example, when vessel
damage or hypoxia is present in the brain, SDF-1 is released from
blood vessels and stem cells, which signals the recruitment of
EPCs to the site of injury to aid in repair. IGF-1 is also critical for
vascular remodeling and tissue repair as its release into the brain
promotes neuronal growth and survival (Madathil et al., 2010).
IGF-1 also assists in oligodendrocytematuration andmyelination
(Mason et al., 2003). In multiple animal studies of brain ischemia,
IGF-1 administration has been shown to reduce neuronal cell
death and stimulated glial cell proliferation (Liu et al., 2001; Lin
et al., 2009).
These data indicate the significant role that EPCs could
play in neuroprotection through the regeneration of strong
and long lasting blood vessel networks in brain regions at risk
of damage. Thus, while EPCs demonstrate multiple potential
neuroprotective functions, it is principally their capacity for
blood vessel regeneration that has great use in the setting of
chorioamnionitis and neuroinflammation.
Umbilical cord tissue and UCB are excellent sources of MSCs
and EPCs, respectively. It is important to elucidate the potential
for these cells independently, or as a combined therapy where
EPCs and MSCs could be co-administered as a potential targeted
therapy for chorioamnionitis and damage to the developing
brain.
CONCLUSION
Chorioamnionitis and preterm birth are significant contributors
to perinatal injury, and often co-exists. The consequences of
fetal exposure to infection are complex, mediated by downstream
systemic and cerebral hypoxic and inflammatory events that
contribute to brain injury. It is known that chorioamnionitis
and preterm birth are primary causes of perinatal brain injury
and the subsequent development of CP, but currently there are
no treatments that could be administered after birth to protect
or repair the immature brain. We propose that targeted cell
therapy with UCB or cord tissue MSCs and EPCs could be
a suitable and efficacious solution. Administration of MSCs
soon after birth during the peak phase of neuroinflammation,
followed by the subsequent administration of EPCs to induce
vascular remodeling, may act to normalize brain development
and/or repair the damage consequent to chorioamnionitis.
A combined therapy of UCB endothelial progenitor cells
and cord tissue MSCs warrants further investigation as a
neonatal therapy to reduce the burden of perinatal brain
injury and CP.
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